Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment.

Federica Sotgia  
Manchester Breast Centre and Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, Manchester, M20 4BX, UK; The Jefferson Stem Cell Biology and Regenerative Medicine Center; Departments of Stem Cell Biology and Regenerative Medicine, and Cancer Biology, Thomas Jefferson University

Ubaldo E Martinez-Outschoorn  
Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University; The Jefferson Stem Cell Biology and Regenerative Medicine Center; Departments of Stem Cell Biology and Regenerative Medicine, and Cancer Biology, Thomas Jefferson University

Stephanos Pavlides  
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Departments of Stem Cell Biology and Regenerative Medicine, and Cancer Biology, Thomas Jefferson University

Anthony Howell  
Manchester Breast Centre and Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, Manchester, M20 4BX, UK

Richard G. Pestell  
Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University; The Jefferson Stem Cell Biology and Regenerative Medicine Center; Departments of Stem Cell Biology and Regenerative Medicine, and Cancer Biology, Thomas Jefferson University

Richard G. Pestell, Michael P; "Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment." (2011). Department of Stem Cell Biology and Regenerative Medicine Faculty Papers & Presentations. Paper 3.  
https://jdc.jefferson.edu/stem_regenerativefp/3

Recommended Citation  
Sotgia, Federica; Martinez-Outschoorn, Ubaldo E; Pavlides, Stephanos; Howell, Anthony; Pestell, Richard G.; and Lisanti, Michael P, "Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment." (2011). Department of Stem Cell Biology and Regenerative Medicine Faculty Papers & Presentations. Paper 3.  
https://jdc.jefferson.edu/stem_regenerativefp/3

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Stem Cell Biology and Regenerative Medicine Faculty Papers & Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
The conventional 'Warburg effect' versus oxidative mitochondrial metabolism

The Warburg effect, also known as aerobic glycolysis, is defined as the propensity of cancer cells to take up high levels of glucose and to secrete lactate in the presence of oxygen. Warburg's original work indicated that while glucose uptake and lactate production are greatly elevated, a cancer cell's rate of mitochondrial respiration is similar to that of normal cells [1,2]. He, however, described it as a 'respiratory impairment' due to the fact that, in cancer cells, mitochondrial respiration is smaller, relative to their glycolytic power, but not smaller relative to normal cells. He recognized that oxygen consumption is not diminished in tumor cells, but that respiration is disturbed because glycolysis persists in the presence of oxygen [1,2]. Unfortunately, the perception of his original findings was simplified over the years, and most subsequent papers validated that cancer cells undergo aerobic glycolysis and produce lactate, but did not measure mitochondrial respiration, and just presumed decreased tricarboxylic acid (TCA) cycle activity and reduced oxidative phosphorylation [1,2]. It is indeed well documented that, as a consequence of intra-tumoral hypoxia, the hypoxia-inducible factor (HIF)1α pathway is activated in many tumors cells, resulting in the direct up-regulation of lactate dehydrogenase (LDH) and increased glucose consumption. For updated reviews on the Warburg effect, the reader is encouraged to refer to the following papers [3,4].

However, new findings compel us to reconsider the current model of cancer cell metabolism. First, not all tumors are associated with increased aerobic glycolysis,
and in fact it is now clear that cancer cells utilize both glycolysis and oxidative phosphorylation to satisfy their metabolic needs. Experimental assessments of ATP production in cancer cells have demonstrated that oxidative pathways play a significant role in energy generation, and may be responsible for about 50 to 80% of the ATP generated [5-8]. Also, it should be considered that most studies were performed using isolated cancer cells, which may behave very differently from cancer cells in vivo, surrounded by their natural microenvironment [9] (see also Koukourakis and colleagues [10] for another viewpoint).

Second, several studies now clearly indicate that mitochondrial activity and oxidative phosphorylation support tumor growth. Loss-of-function mutations in the TCA cycle gene IDH1 (isocitrate dehydrogenase 1) are found in about 70% of gliomas, but, interestingly, correlate with a better prognosis and improved survival, suggesting that severely decreased activity in one of the TCA cycle enzymes does not favor tumor aggressiveness [11]. The mitochondrial protein p32 was shown to maintain high levels of oxidative phosphorylation in human cancer cells and to sustain tumorigenicity in vivo [12]. In addition, STAT3 is known to enhance tumor growth and to predict poor prognosis in human cancers [13]. Interestingly, a pool of STAT3 localizes to the mitochondria, to sustain high levels of mitochondrial respiration [14] and to augment transformation by oncogenic Ras [15,16]. Similarly, the mitochondrial transcription factor A (TFAM), which is required for mitochondrial DNA replication and oxidative phosphorylation, is also required for K-Ras-induced lung tumorigenesis [17]. Finally, when constrained to use glycolysis by depletion of mitochondrial DNA, melanoma B16 cells (B16p0) and breast cancer T47D cells (T47Dp0), show severe impairment of tumorigenicity in vivo [18,19].

There is also evidence that pro-oncogenic molecules regulate mitochondrial function. Cyclin D1 inhibits mitochondrial function in breast cancer cells [20]. Overexpression of cyclin D1 is observed in about 50% of invasive breast cancers and is associated with a good clinical outcome [21], indicating that inhibition of mitochondrial activity correlates with favorable prognosis. Importantly, it was shown that the oncogene c-Myc stimulates mitochondrial biogenesis, and enhances glutamine metabolism by regulating the expression of mitochondrial glutaminase, the first enzyme in the glutamine utilization pathway [22]. Glutamine is an essential metabolic fuel that is converted to alpha-ketoglutarate and serves as a substrate for the TCA cycle or for glutathione synthesis, to promote energy production and cellular biosynthesis, and to protect against oxidative stress [23]. Interestingly, pharmacological targeting of mitochondrial glutaminase inhibits cancer cell transforming activity, suggesting that glutamine metabolism and its role in fueling and replenishing the TCA cycle are required for neoplastic transformation [24] (for a recent review on glutamine cancer metabolism, see [2]).

**The reverse Warburg effect**

It is increasingly apparent that the tumor microenvironment regulates neoplastic growth and progression. Activation of the stroma is a critical step required for tumor formation. Among the stromal players, cancer associated fibroblasts (CAFs) have recently taken center stage [25]. CAFs are activated, contractile fibroblasts that display features of myo-fibroblasts, express muscle-specific actin, and show an increased ability to secrete and remodel the extracellular matrix [26,27]. They are not just neutral spectators, but actively support malignant transformation [28] and metastasis [29], as compared to normal resting fibroblasts. For example, in a humanized mouse model of breast cancer, oncogenically driven human organoids develop tumors only if co-injected with immortalized fibroblasts and not with normal primary fibroblasts, suggesting that stromal activation is required for breast cancer formation [30].

Importantly, the tumor stroma dictates clinical outcome and constitutes a source of potential biomarkers [31]. Expression profiling has identified a cancer-associated stromal signature that predicts good and poor clinical prognosis in breast cancer patients, independently of other factors [32-34].

We and others have recently shown that a loss of caveolin-1 (Cav-1) in the stromal compartment is a novel biomarker for predicting poor clinical outcome in all of the most common subtypes of human breast cancer, including the more lethal triple negative subtype [35,36]. A loss of stromal Cav-1 predicts early tumor recurrence, lymph-node metastasis, tamoxifen-resistance, and poor survival. Overall, breast cancer patients with a loss of stromal Cav-1 show a 20% 5-year survival rate, compared to the 80% 5-year survival of patients with high stromal Cav-1 expression. In triple negative patients, the 5-year survival rate is 75.5% for high stromal Cav-1 versus 9.4% for absent stromal Cav-1 [37]. A loss of stromal Cav-1 also predicts progression to invasive disease in ductal carcinoma in situ patients, suggesting that a loss of Cav-1 regulates tumor progression [35]. Similarly, a loss of stromal Cav-1 is associated with advanced disease and metastasis, as well as a high Gleason score, in prostate cancer patients [38].

In order to mechanistically dissect how a loss of stromal Cav-1 induces a lethal microenvironment, we have employed Cav-1(−/−) null mice as a model system. Complementary studies were also performed with a co-culture model of normal human fibroblasts and MCF7 breast cancer cells.

Unbiased proteomic and transcriptional analysis has shown that Cav-1(−/−) null bone-marrow-derived stromal
cells display the up-regulation of both myo-fibroblast markers and glycolytic enzymes, clearly indicating that a loss of Cav-1 promotes myo-fibroblast conversion and induces aerobic glycolysis in stromal cells [39]. Thus, stromal cells lacking Cav-1 undergo aerobic glycolysis and secrete energy-rich metabolites (such as lactate and pyruvate) that directly feed cancer cells and fuel mitochondrial respiration of adjacent cancer cells. We have termed this novel hypothesis the ‘reverse Warburg effect.’ This novel idea has now also been independently confirmed by Pol and colleagues [40], who demonstrated that genetic ablation of Cav-1 in murine fibroblasts is indeed sufficient to functionally induce the onset of aerobic glycolysis via mitochondrial dysfunction [40]. Interestingly, immunohistochemistry on human breast cancers lacking stromal Cav-1 has demonstrated the over-expression of key glycolytic enzymes, such as PKM2 and LDH, in the fibroblastic tumor stroma [39].

In further support of this hypothesis, co-culture with cancer cells promotes Cav-1 down-regulation in adjacent fibroblasts. Importantly, when cultured under homotypic conditions, MCF7 cancer cells have a very low mitochondrial mass (the conventional Warburg effect). However, co-culture with fibroblasts, which more closely mirrors the microenvironment of a naturally occurring tumor, promotes a very significant increase in mitochondrial mass in MCF7 cancer cells, suggesting that the Warburg effect might be an in vitro artifact [41]. Importantly, lactate administration to homotypic MCF7 cancer cell cultures significantly increases mitochondrial mass, suggesting that lactate administration phenocopies the presence of reactive fibroblasts [41], by promoting mitochondrial biogenesis. These new data indicate that cancer cells and CAFs develop a ‘symbiotic’ or ‘parasitic’ relationship, with the vectorial and unilateral transfer of energy from glycolytic stromal cells to oxidative cancer cells (Figures 1 and 2).

Clinically, high glucose uptake has been exploited to monitor tumor growth using position emission tomography (PET) scanning via radiolabeled 2-deoxy-glucose. However, we should acknowledge that PET avidity does not necessarily correlate with high aerobic glycolysis. For example, PET is not useful in clear cell renal carcinomas [42,43], which are the tumor ‘prototype’ in which the Warburg effect should sustain tumor formation. About half of clear cell renal carcinomas are due to mutations in the Von Hippel-Lindau (VHL) gene [44,45], leading to HIF1α constitutive activation and forced induction of aerobic glycolysis [46-48]. Conversely, little attention is paid to understanding which cell-type or compartments within a tumor are most PET avid. In fact, the clinical use of PET is well established in Hodgkin’s lymphomas [49], which are composed of less than 10% tumor cells, the rest being stromal and inflammatory cells [50]. Yet, Hodgkin’s lymphomas are very PET avid tumors, suggesting that 2-deoxy-glucose uptake may be associated with the tumor stroma. That the fibrotic component may be glucose avid is further supported by the notion that PET is clinically used to assess the therapeutic response in gastrointestinal stromal tumors (GIST), which are a subset of tumors of mesenchymal origin. Finally, pilot clinical studies have shown that PET is useful for detection of various forms of fibrosis, including pulmonary fibrosis [51].

The reverse Warburg effect can also be described as ‘metabolic coupling’ between supporting glycolytic stromal cells and oxidative tumor cells. Metabolic cooperativity between adjacent cell compartments is observed in several normal physiological settings. During folliculogenesis and early embryogenesis, oocytes are surrounded by supporting cumulus granulosa (CG) cells. Oocytes lack some crucial metabolic functions, such as the ability to utilize glucose, to produce cholesterol and to transport certain amino acids. Thus, oocytes control CG cell metabolism, promoting their glycolysis, cholesterol synthesis and amino acid uptake [52,53]. Remarkably, both oocytes and zygotes can reach a two-cell stage only in the presence of pyruvate and oxaloacetate, but not using glucose [54,55]. However, upon co-culture with CG cells, oocytes or zygotes can cleave to a two-cell stage also in the presence of glucose, clearly indicating that CG cells metabolize glucose and supply the oocyte with the
glycolytic product pyruvate to permit maturation [54]. In this regard, transcriptional profiling of CG cells and oocytes has revealed that key enzymes of the glycolytic pathway (aldolase A, enolase 1, LDHA, and PKM2) are very highly expressed in CG cells, but are undetectable in oocytes [56]. These results indicate that granulosa cells support the development and maturation of oocytes and early embryos by providing them with essential nutrients, such as oxidative phosphorylation substrates (pyruvate and lactate [57]), amino acids [58], and cholesterol [59].

Metabolic coupling is also normally observed in the brain between astrocytes and neurons, and this is known as ‘neuron-glia metabolic coupling’ [60,61]. In this regard, glycolytic astrocytes generate high levels of lactate to support mitochondrial oxidative phosphorylation in adjacent neurons. Consistent with this idea, LDH is preferentially expressed in astrocytes, and the mitochondrial enzyme pyruvate dehydrogenase is present selectively within the neurons [62,63]. Also, in skeletal muscle it is well established that glycolytic fast-twitch muscle fibers produce lactate, which is then secreted via monocarboxylate transporter (MCT) 4. Lactate is then taken up by the slow-twitch fibers expressing MCT1 and utilized as a substrate for oxidative phosphorylation [64,65]. This form of metabolic coupling is known as the ‘skeletal muscle lactate shuttle’ [66].

As such, it is perhaps not surprising that tumors may have also developed a form of metabolic coupling, specifically involving tumor-stromal interactions. In further support of the existence of a ‘lactate shuttle’ in human tumors, we have now shown that CAFs express MCT4 (for lactate extrusion), while breast cancer cells express MCT1 (for lactate uptake) (Figure 3) [67]. Interestingly, MCT4 expression in CAFs is induced by oxidative stress, and MCT4 is a known HIF1α target gene (see Discussion below) [67].

---

**Figure 2. The reverse Warburg effect.** (a) Via oxidative stress, cancer cells activate two major transcription factors in adjacent stromal fibroblasts (hypoxia-inducible factor (HIF)1α and NFκB). This leads to the onset of both autophagy and mitophagy, as well as aerobic glycolysis, which then produces recycled nutrients (such as lactate, ketones, and glutamine). These high-energy chemical building blocks can then be transferred and used as fuel in the tricarboxylic acid cycle (TCA) in adjacent cancer cells. The outcome is high ATP production in cancer cells, and protection against cell death. ROS, reactive oxygen species. (b) Homotypic cultures (upper panels) of MCF7 cells (right) and hTERT-fibroblasts (left) were immunostained with a mitochondrial membrane antibody (red). Note that mitochondrial mass is lower in mono-cultures of MCF7 cells compared to fibroblasts. However, co-culture of MCF7 cells with fibroblasts (lower panel) induces a dramatic increase in mitochondrial mass in the central MCF7 cell colony, outlined by the dotted white oval. In contrast, mitochondrial mass is decreased in co-cultured fibroblasts. Panel (b) was modified and reproduced with permission from [41,78].

---
Oxidative stress: random mutagenesis and protection against cell death

Recent studies have dissected the mechanism(s) by which a loss of stromal Cav-1 leads to an aggressive breast cancer phenotype, and have shown that oxidative stress plays a central role. The role of oxidative stress in sustaining tumor growth is underscored by the observation that reactive oxygen species (ROS)-mediated myo-fibroblast conversion is sufficient to reduce tumor-free survival, and increases metastatic potential in a mammary tumor mouse model [68].

Gene expression profiling of Cav-1(-/-) null bone-marrow-derived stromal cells has shown the up-regulation of gene transcripts associated with ROS production, and over-expression of the transcriptional targets of HIF1α and NFκB, suggesting that a loss of stromal Cav-1 induces oxidative stress, mimics hypoxia, and stimulates inflammation [41].

Co-cultures of normal human fibroblasts and MCF7 cells indicate that cancer cells use oxidative stress as a weapon to trigger the conversion of adjacent fibroblasts into myo-fibroblasts [69]. Cancer cell-induced oxidative stress
stress potently perturbs the behavior of adjacent fibroblasts, induces the lysosomal-mediated degradation of Cav-1, and promotes mitochondrial dysfunction, resulting in increased aerobic glycolysis [41]. In turn, these glycolytic fibroblasts support tumor cell mitochondrial respiration and growth by actively transferring high-energy nutrients (such as lactate and pyruvate) to cancer cells.

In support of the ‘reverse Warburg effect’, comparison of the tumor-promoting properties of two fibroblast lines (named CL3 and CL4) with either mitochondrial or glycolytic metabolism has revealed that aerobic glycolysis in CAFs greatly promotes tumor formation. CL3 fibroblasts show oxidative metabolism and increased mitochondrial mass, whereas CL4 fibroblasts display a shift towards aerobic glycolysis and increased lactate production [70]. Interestingly, in a xenograft model, CL4 fibroblasts enhance the growth of mammary tumors by approximately eight-fold compared to CL3 cells, without a detectable increase in angiogenesis. Consistent with this growth-promoting effect, CL4 fibroblasts also increase the mitochondrial mass of co-cultured breast cancer cells [71].

An oxidative-stress-rich micro-environment generates DNA damage in both cancer and stromal cells (Figure 1). We have shown that MCF7 cancer cells induce oxidative stress and promote DNA double-strand breaks in associated stromal cells, which are blocked by antioxidant treatments [41]. Similarly, after three-dimensional co-culture with prostate cancer cells, bone-derived stromal cells undergo stable cytogenetic modifications by a ROS-mediated mechanism [72].

Conversely, in an MCF7-fibroblast co-culture model, MCF7 cancer cells undergo aneuploidy and random mutagenesis [41], suggesting that CAFs facilitate the dynamic search for a more aggressive ‘mutator phenotype’ in cancer cells (Figure 1). Functionally, fibroblasts provide cancer cells with a six-fold protection against cell death [41] (Figure 2), via the up-regulation of the anti-apoptotic protein TIGAR [41]. Cav-1 knockdown fibroblasts provide even greater protection for cancer cells against apoptosis, clearly indicating that a loss of stromal Cav-1 in humans may greatly facilitate tumor growth by suppression of cancer cell death [41].

Thus, data supporting the ‘reverse Warburg effect’ indicate that cancer cells and fibroblasts are metabolically coupled and mutagenically co-evolving [41,73]. Cancer cells use oxidative stress to corrupt adjacent fibroblasts and to induce their metabolic re-programming [73]. In this way, fibroblasts secrete energy rich metabolites that facilitate cancer cell survival. In addition, fibroblasts promote mutagenesis of cancer cells, leading to a more aggressive ‘aneuploid’ phenotype [41,73]. Aneuploidy in cancer cells is known to be associated with poor clinical outcome.

Hypoxia, autophagy, and mitophagy in the tumor stroma

Metabolomic profiling reveals that Cav-1(-/-) null mammary fat pads display a highly catabolic metabolism, with the increased release of several metabolites, such as amino acids, ribose and nucleotides, and a shift towards gluconeogenesis, as well as mitochondrial dysfunction [74]. These changes are consistent with increased autophagy, mitophagy and aerobic glycolysis, all processes that are induced by oxidative stress [74]. Autophagy or ‘self-eating’ is the process by which cells degrade their own cellular components to survive during starvation or to eliminate damaged organelles after oxidative stress. Mitophagy, or mitochondrial-autophagy, is particularly important to remove damaged ROS-generating mitochondria.

An autophagy/mitophagy program is also triggered by hypoxia [75,76]. Hypoxia is a common feature of solid tumors, and promotes cancer progression, invasion and metastasis [77]. Interestingly, via induction of autophagy, hypoxia is sufficient to induce a dramatic loss of Cav-1 in fibroblasts. The hypoxia-induced loss of Cav-1 can be inhibited by the autophagy inhibitor chloroquine, or by pharmacological inhibition of HIF1α [69,78]. Conversely, small interfering RNA-mediated Cav-1 knock-down is sufficient to induce pseudo-hypoxia, with HIF1α and NFXb activation, and to promote autophagy/mitophagy, as well as a loss of mitochondrial membrane potential in stromal cells [78]. These results indicate that a loss of stromal Cav-1 is a marker of hypoxia and oxidative stress.

In a co-culture model, autophagy in cancer-associated fibroblasts was shown to promote tumor cell survival via the induction of the pro-autophagic HIF1α and NFXb pathways in the tumor stromal microenvironment [78]. Finally, the mitophagy marker Bnip3L is selectively up-regulated in the stroma of human breast cancers lacking Cav-1, but is notably absent from the adjacent breast cancer epithelial cells [78].

Another study has shown that cell-specific induction of autophagy by HIF1α activation in fibroblasts or MDA-MB-231 cells differentially affects tumor growth. In a xenograft model, HIF1α activation in fibroblasts greatly enhances the tumorigenicity of co-injected MDA-MB-231 cells, whereas HIF1α activation in MDA-MB-231 cancer cells suppresses tumor growth [79]. Importantly, in this experimental setting, the levels of tumor angiogenesis were unchanged. As HIF1α triggers autophagy in both fibroblasts and cancer cells, these data demonstrate that the role of autophagy in driving tumor formation is cell-type specific, and that stromal autophagy, and not cancer cell autophagy, favors tumor growth.

Several studies have demonstrated that the over-expression of autophagic markers, such as ATG16L and cathepsin K and D, in the stroma and not in tumor cells
predicts poor prognosis [80-82]. Similarly, loss of autophagic markers, such as Beclin 1, in tumor cells correlates with poor clinical outcome, suggesting that activation of an autophagic program in tumor cells reduces tumor aggressiveness [83].

Metabolome profiling of several types of human cancer tissues versus corresponding normal tissues have consistently shown that cancer tissues are highly catabolic, with the significant accumulation of many amino acids and TCA cycle metabolites [84,85]. The levels of reduced glutathione were decreased in primary and metastatic prostate cancers compared to benign adjacent prostate tissue, suggesting that aggressive disease is associated with increased oxidative stress [86]. Also, these data show that the tumor microenvironment has increased oxidative-stress-induced autophagy and increased catabolism.

Taken together, all these findings suggest an integrated model whereby a loss of stromal Cav-1 induces autophagy/mitophagy in the tumor stroma, via oxidative stress. This creates a catabolic micro-environment with the local accumulation of chemical building blocks and recycled nutrients (such as amino acids and nucleotides), directly feeding cancer cells to sustain their survival and growth. We have termed this novel idea the ‘autophagic tumor stroma model of cancer’ [74]. This new paradigm may explain the ‘autophagy paradox’, which is based on the fact that both the systemic inhibition and systemic stimulation of autophagy prevent tumor formation [87]. We propose that vectorial energy transfer from the tumor stroma to cancer cells directly sustains tumor growth, and that interruption of such metabolic coupling will block tumor growth. Autophagy inhibitors (such as chloroquine) functionally block the catabolic transfer of metabolites from the stroma to the tumor, inducing cancer cell starvation and death [88]. Conversely, autophagy inducers (such as rapamycin) promote autophagy in tumor cells and induce cell death [89]. Thus, both inhibitors and inducers of autophagy will have a similar effect by severing the metabolic coupling of the stroma and tumor cells, resulting in tumor growth inhibition (cutting off the fuel supply).

This model may also explain why enthusiasm for anti-angiogenic therapy has been dampened. In most cases, the clinical benefits are short term, and more importantly, new data suggest an unexpected link between anti-angiogenic treatments and metastasis. In pre-clinical models, anti-vascular endothelial growth factor (anti-VEGF) drugs (sunitinib and anti-VEGFR2 blocking antibodies) were shown to inhibit localized tumor formation, but potently induced relapse and metastasis [90-92]. Thus, by inducing hypoxia in the tumor microenvironment, anti-angiogenic drugs may create a more favorable metastatic niche [93]. Hypoxia-induced autophagy may play a role by generating a catabolic micro-environment rich in chemical building blocks that can be directly used by cancer cells to sustain malignant transformation and metastatic progression.

Finally, the autophagic tumor stroma model can also provide an explanation for systemic cachexia, which is progressive skeletal muscle and adipose tissue wasting, affecting up to 50% of all cancer patients and resulting in severe weight loss and shortened survival [94]. Cachexia is the result of increased energy consumption and higher metabolic rates [95]. Based on our data, we envision that cancer leads to a generalized catabolic state via an autophagic-mechanism that generates building blocks and starves the rest of the body. While the exact signaling pathways governing this phenomenon are not yet fully elucidated, it is clear that oxidative stress-induced autophagy functions as a driver of muscle wasting [96]. For example, skeletal muscles from tumor-bearing mice showed impaired Akt activation and a more than 50-fold induction of Bnip3, a well recognized marker of autophagy/mitophagy [97]. These findings also help explain why patients with metabolic syndrome and diabetes have an increased risk for the development of multiple epithelial cancers, due to their constitutive and systemic activation of the autophagic program, and the over-production of high-energy nutrients, such as lactate and ketones [74].

We have recently used laser-capture micro-dissection of the tumor stroma from human breast cancers to directly validate that a loss of stromal Cav-1 is transcriptionally associated with oxidative stress, hypoxia, autophagy, and mitochondrial dysfunction, via gene-set enrichment analysis (Figure 4) [98]. In addition, we see that oxidative stress in CAFs induces cytokine production via NFκB activation, directly linking inflammation with autophagy/catabolism in the tumor stroma [99]. So, cachexia may start locally as stromal autophagy, and then spread systemically via cytokine production and inflammation, which also drive autophagy [99].

**Glutamine utilization, ammonia production, and autophagy in the tumor stroma**

In direct support that cancer cells use mitochondrial oxidative metabolism, many investigators have shown that cancer cells are ‘addicted’ to glutamine [24,100]. Glutamine is a non-essential amino acid that is metabolized to glutamate and enters the TCA cycle as alphaketoglutarate, resulting in high ATP generation via oxidative phosphorylation [2,22,101-103].

Recent studies also show that ammonia is a by-product of glutaminolysis [104-106]. In addition, ammonia can act as a diffusible inducer of autophagy [104-106]. Given these observations, glutamine addiction in cancer cells provides another mechanism for driving and/or...
Figure 4. Molecular profiling of a Cav-1 deficient tumor micro-environment in breast cancer patients. (a) The transcriptional profiles of cavedolin-1 (Cav-1)-positive (+) tumor stroma (N = 4) versus Cav-1-negative (-) tumor stroma (N = 7) were compared, via laser-capture microdissection. We identified 238 gene transcripts that were up-regulated and 232 gene transcripts that were down-regulated in the stroma of tumors showing a loss of Cav-1 expression. Note that the two patient populations are transcriptionally distinct. (b) The Cav-1-deficient stromal gene signature is associated with poor survival in estrogen receptor-positive and luminal A breast cancer patients. Note that the Cav-1-deficient stromal signature is clearly associated with decreased overall survival. (c) Heat maps of the gene transcripts associated with the response to hypoxia, glycolysis, and autophagy. Note that Cav-1-deficient stroma shows the up-regulation of hypoxia target genes (65 transcripts), glycolysis/pyruvate metabolism (15 transcripts), and autophagy (22 transcripts). Modified and reproduced with permission from [98].
maintaining autophagy in the tumor micro-environment (Figure 5). In support of this idea, we have previously shown that a loss of Cav-1 in the stroma is sufficient to drive autophagy, resulting in increased glutamine production in the tumor micro-environment [74].

Thus, this concept defines a new vicious cycle in which autophagy in the tumor stroma transfers glutamine to cancer cells, and the by-product of this metabolism, ammonia, maintains autophagic glutamine production (Figure 5). This model fits well with the ‘autophagic tumor stroma model of cancer metabolism’, in which energy-rich recycled nutrients (lactate, ketones, and glutamine) fuel oxidative mitochondrial metabolism in cancer cells.

**Lessons from other paradigms: an infectious parasitic cancer cell that metastasizes and captures mitochondrial DNA from host cells**

We have recently proposed that cancer cells behave like ‘parasites’, by inducing oxidative stress in normal host fibroblasts, resulting in the production of recycled nutrients via autophagy [41,69,78]. This is exactly the same mechanism by which infectious parasites (such as malaria) obtain nutrients and are propagated by inducing oxidative stress and autophagy in host cells [107-109]. In this regard, malaria is an ‘intracellular’ parasite, while cancer cells may be thought of as ‘extracellular’ parasites. This explains why chloroquine is both an effective anti-malarial drug and an effective anti-tumor agent, as it functions as an autophagy inhibitor [110], cutting off the ‘fuel supply’ in both disease states.

Are there any examples of cancer cells that act as infectious parasites? Surprisingly, the answer is yes [111]. There are four known types: canine transmissible venereal tumor (CTVT), which is a sexually transmitted disease that occurs in feral dogs [112] - it is transmitted through coitus, licking/biting, or sniffing; devil facial tumor disease, spread among Tasmanian devils via facial biting [113,114]; contagious reticulum cell sarcoma, which is transmitted between Syrian hamsters via mosquito bites [115,116]; and malignant fibrous histiocytoma, which was transmitted from a cancer patient to his surgeon [117] during an injury that occurred when the surgeon was operating.

These parasitic cancers are all transmitted by allografting, so the cancer cells literally ‘metastasize’ from one affected host to another ‘naïve’ host, in an infectious manner that does not involve a virus.

Experimentally, the most is known about CTVT. This disease is thought to have originated in ancient wolves or coyotes, and the tumor cells themselves act as the infectious agent. As such, these cancer cells are genetically distinct from their hosts, as determined by genomic sequence analysis of their nuclear DNA [118]. CTVT represents the oldest known cancer cell line that has been continuously propagated, most likely for more than 10,000 years [118,119].

Interestingly, it has recently been shown that CTVT tumor cells survive by periodically capturing ‘mitochondrial DNA from their hosts [119,120]. Thus, it has been suggested that these CTVT tumor cells have survived for more than 10,000 years by maintaining and renewing their capacity for oxidative mitochondrial metabolism by ‘stealing’ host cell mitochondrial DNA [119,120]. In accordance with this idea, CTVT is highly sensitive to adriamycin/doxorubicin therapy [121], a chemo-therapeutic agent that also functions as a mitochondrial poison.

Similarly, it has been independently shown that human cancer cells can ‘steal’ live mitochondria or mitochondrial DNA [122] from adjacent mesenchymal stem cells in culture, which then rescues aerobic glycolysis in these cancer cells [122]. This is known as mitochondrial transfer [122]. Interestingly, others have shown that metastatic breast cancer cells show the up-regulation of numerous mitochondrial proteins [123], specifically

---

**Figure 5. Glutamine utilization in cancer cells and the tumor stroma.** Oxidative mitochondrial metabolism of glutamine in cancer cells produces ammonia. Ammonia production is sufficient to induce autophagy. Thus, autophagy in cancer-associated fibroblasts provides cancer cells with an abundant source of glutamine. In turn, the ammonia produced maintains the autophagic phenotype of the adjacent stromal fibroblasts. See text for details. TCA, tricarboxylic acid.
consistent with experiments showing that intraperitoneal injection of lactate in an MDA-MB-231 xenograft model results in an approximately ten-fold increase in lung metastasis [125].

**Abbreviations**

CAF, cancer associated fibroblast; Cav, caveolin; CTVT, canine transmissible venereal tumor; HIF, hypoxia-inducible factor; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; NF, nuclear factor; PET, position emission tomography; ROS, reactive oxygen species; TCA, tricarboxylic acid.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgements**

MPL and his laboratory were supported by grants from the NIH/NCI (R01-CA-080250; R01-CA-098770; R01-CA-120876; R01-AR-055660), and the Susan G Komen Breast Cancer Foundation. FS was supported by grants from the WW Smith Charitable Trust, the Breast Cancer Alliance (BCA), and a Research Scholar Grant from the American Cancer Society (ACS). RGP was supported by grants from the NIH/NCI (R01-CA-70896, R01-CA-75503; R01-CA-86072, and R01-CA-107382) and the Dr Ralph and Marian C Falk Medical Research Trust. The Kimmel Cancer Center was supported by the NIH/NCI Cancer Center Core grant P30-CA-56036 (to RGP). Funds were also contributed by the Margaret Q. Landenberger Research Foundation to MPL. This project is funded, in part, under a grant with the Pennsylvania Department of Health (to MPL). The Department specifically disclaims responsibility for any interpretations or conclusions. This work was also supported, in part, by a Centre grant in Manchester from Breakthrough Breast Cancer in the UK (to AH) and an Advanced ERC Grant from the European Research Council. Dr MP Lisanti would especially like to thank Drs Craig B Thompson, Tak W Mak, Michel L Tremblay, and Robert S DiPaola (other participants of the ASMB/AACR 2011 Meetings) for their feedback, thoughtful comments, and helpful suggestions. This review was recently presented as a lecture at the AACR 2011 Meeting in the Educational Session Autophagy and Cell Death on 2 April 2011 (Orlando, FL). It was also presented as a lecture at the Experimental Biology 2011-ASMB Meeting (Washington, DC) at the session 'Metabolism and Cancer’ on 13 April 2011.

**Author details**

1The Jefferson Stem Cell Biology and Regenerative Medicine Center, Philadelphia, PA 19107, USA. 2Departments of Stem Cell Biology and Regenerative Medicine, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA. 3Manchester Breast Centre and Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, Manchester, M20 4BX, UK. 4Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

**Published: 8 July 2011**

**References**

1. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
2. Dang CV. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect. Sci Signal 2009, 2pe75.
3. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
4. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB: Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2009, 19:54-61.
5. Guppy M, Leedman P, Xu Z, Russell V: Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J 2002, 364:309-315.
6. Kallinowski F, Vaupe1 P, Runkel S, Berg G, Fortmeyer HP, Baessler KH, Wagner K, Mueller-Klieser W, Walenta S: Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 1988, 48:7264-7272.
7. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 2004, 313:459-465.
8. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okuneff P, Vaupe1 P: Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 1989, 49:3759-3764.
9. Gstraunthaler G, Seppi T, Pfaller W: Impact of culture conditions, culture...
media volumes, and glucose content on metabolic properties of renal epithelial cell cultures. Are renal cells in tissue culture hypoxic? Cell Physiol Biochem 1999, 9:150-172.

10. Kookourakis MI, Girotomanaki A, Harris AL, Sviridis E: Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stromal cells. Cancer Res 2006, 66:652-637.

11. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinec-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velecsu CE, Volgenau B, Biggins DH: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.

12. Fogo V, Richardson AO, Kamali PB, Scheffer E, Smith JW, Ruoslahti E: Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol 2010, 30:1303-1318.

13. Sheen-Chen SM, Huang CC, Tang RP, Chou FF, Eng HL: Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Biomarkers 2008, 17:2266-2290.

14. Wegrzyn J, Porla R, Chwae YJ, Serpin NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szlega M, Gompka A, Moh A, Moghaddas S, Chen Q, Bobbli S, Cichy J, Dulak J, Baker DP, Wolfman A, Stuehr D, Hassan MO, Fu YX, Avadhani N, Dake J, Fiwatt: Pelesneky EF, Larner AC: Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:93-97.

15. Reich NC: STAT3 revs up the powerhouse. Sci Signal 2009, 2:pe61.

16. Gough DJ, Dhillon AS, Schlesinger K, Wegrzyn J, Larner AC, Carey LA: Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.

17. Weinberg F, Hamaoka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Muthu GM, Budinger GR, Chandel NS: Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010, 107:8768-8773.

18. Berridge MV, Tan AS: Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res 2010, 13:139-141.

19. Yu M, Shi Y, Wei X, Yang Y, Zhou Y, Hao X, Zhang N, Niu R: Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of 4T10D human breast cancer cells. Toxicol Lett 2007, 170:83-93.

20. Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu X, Jiao X, Li A, Zhang X, Lu Y, Wang C, Byers S, Nicholson R, Link T, Shemluk M, Yang J, Fricke ST, Novikoff PM, Papanikolaou A, Arnold A, Alibarase C, Pestell R: Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol 2006, 26:5449-5469.

21. Bostrom P, Soderstrom M, Polakangas T, Vahlberg T, Collan Y, Carpen O, Hiruna M: Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour size and other prognostic factors. BMC Res Notes 2009, 2:140.

22. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeiler KL, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV: c-Myc suppression of mitr-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.

23. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Brody JR, Mitchell EP: Loss of mitochondrial cyclin expression predicts clinical outcome in breast cancer. Nat Med 2008, 14:518-527.

24. Ma XJ, Daihia S, Richardson E, Erlander M, Sgroi DC: Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009, 11:R37.

25. Bianchini G, Zv Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Purzafl: Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010, 28:4316-4323.

26. Witkiewicz AK, Casimiro WC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, Jasmin JR, Frank PG, Pestell RG, Klein CG, Sotgia F, Lisanti MP: Towards a new "stroma-based" classification system for human breast cancer progression and therapy. Cell Cycle 2009, 8:1654-1658.

27. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M: Caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010, 10:135-143.

28. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP: An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009, 8:2420-2424.

29. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP: The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.

30. Bosch M, Mari M, Herms A, Fernandez A, Fajardo A, Kassan A, Giralt A, Colaix A, Balgoma D, Barbero E, Gonzalez-Moreno E, Matias N, Tebar F, Balinde J, Camps M, Enrich C, Gross SP, Garcia-Ruiz C, Perez-Navarro E, Fernandez-Checa JC, Pol A: Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. Curr Biol 2011, 21:681-686.

31. Martinez-Outschoorn UE, Balliet RM, Omeroglu G, Milementak A, Sotgia F, Lisanti MP: The molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. Breast Cancer Res 2011, 11:R7.

32. Avril N, Damhia F, Murray J, Shamas J, Powles T, Sahdev A: The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/ computed tomography in urological cancers. Int J Urol 2010, 17:501-511.

33. Gnarra JR, Tony K, Weng Y, Schmidt L, Wei MH, Li H, Latf F, Liu S, Chen F, Duh FM, et al.: Mutations of the VHL tumor suppressor gene in renal cell carcinoma. Nat Genet 1994, 7:65-90.

34. Cosvey CL, Rathmell WK: VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009, 11:94-101.

35. Tanimoto K, Makino Y, Pereira T, Poellinger L: Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000, 19:4398-4409.

36. Kamura T, Sato S, Iwai K, Czyz-Krzyzewska M, Conaway RC, Conaway JW: Activation of HIF alpha ubiquitination by a reconstituted von
Hippel-Lindau (VHL) tumor suppressor complex. *Proc Natl Acad Sci U S A* 2000, 97:10430-10435.

48. Ohm M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. *Nat Cell Biol* 2000, 2:431-437.

49. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O. 18F-FDG avidity in lymphoma: a study of 766 patients. *J Nucl Med* 2010, 51:25-30.

50. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. *J Pathol* 2010, 221:248-263.

51. Groves AM, Win T, Sceatton NJ, Berovic M, Endozo R, Booth H, Kayani I, Sugiura K, Su YQ, Diaz FJ, Pangas SA, Sharma S, Wigglesworth K, O'Brien MJ.

52. Brinster RL. The pattern of energy metabolism in the mouse oocyte and zygote. *Proc Natl Acad Sci U S A* 1967, 55:560-567.

53. Brinster RL. Studies on the development of mouse embryos in vitro. II. The effect of energy source. *J Exp Zool* 1965, 158:59-68.

54. Sugiuira K, Pendola FL, Eppig JJ. Oocyte regulation of BMP15 and FGFs cooperate to promote glycolysis in cumulus cells. *Development* 2007, 134:2593-2603.

55. Biggers JD, Whittingham DG, Donahue RP. Oxygenation: the mechanism of energy metabolism in the mouse oocyte and zygote. *Proc Natl Acad Sci U S A* 1967, 55:560-567.

56. Brinster RL. Oxidation of pyruvate and glucose by oocytes of the mouse and rhesus monkey. *J Reprod Fertil* 1971, 24:187-191.

57. Colonna R, Mangia F. Mechanisms of amino acid uptake in cumulus-enclosed mouse oocytes. *Biochim Biophys Acta* 1983, 877:805-807.

58. Sugiuira K, Sceatton NJ, Pottola FL, Migneco G, Eppig JJ. Oocyte metabolic cooperation between oocytes and companion granulosa cells: energy metabolism. *Dev Biol* 2005, 279:20-30.

59. Brinster RL. Metabolic coupling between glia and neurons. *Neurosci 1996*, 167:877-885.

60. Brinster RL. Metabolic coupling between glia and neurons. *Neurosci 1996*, 167:877-885.

61. Connors BR, Gaytese TE, Hong CR. Lactate accumulation in fully aerobic, working, dog gracilis muscle. *Am J Physiol* 1984, 246:H120-128.

62. McCullagh KJ, Poole RC, Halestrap AP, Tipton KF, O'Brien M, Bonen A. Chronic electrical stimulation increases MCT1 and lactate uptake in red and white skeletal muscle. *Am J Physiol* 1997, 273:E239-246.

63. Brooks GA. The lactate shuttle during exercise and recovery. *Med Sci Sports Exerc* 1986, 18:360-368.

64. Whitaker-Menezes D, Martinez-Ortuno UE, Lin Z, Erelt A, Flomenberg N, Witkiewicz AK, Birke RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philipp LJ, Sotgia MP. Evidence for a stromal-epithelial 'lactate shuttle' in mouse embryos. *Cell Cycle* 2009, 8:2059-2068.

65. Cathepsin D in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. *Cell Cycle* 2010, 9:535-533.

66. Gaussian D, Sotgia F, Lisanti MP. Oxidative stress and mitrochondrial function in cancer associated fibroblasts. *Cancer Res* 2010, 70:1772-1783.

67. Whitaker-Menezes D, Martinez-Ortuno UE, Lin Z, Erelt A, Flomenberg N, Witkiewicz AK, Birke RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philipp LJ, Sotgia MP. Evidence for a stromal-epithelial 'lactate shuttle' in human tumors: MCT4 is a marker of oxidative stress in cancer associated fibroblasts. *Cell Cycle* 2011, 10:1772-1783.

68. Sotgia F, Lisanti MP. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. *Cell Cycle* 2010, 9:3485-3505.

69. Azad MB, Gibson SB. Role of BNIP3 in proliferation and hypoxia-induced autophagy: implications for personalized cancer therapies. *Ann NY Acad Sci* 2010, 1210:18-16.

70. Sotgia F, Lisanti MP. Oxidative stress and ketone production in cancer associated fibroblasts promote tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. *Cell Cycle* 2010, 9:3534-3531.

71. Sotgia F, Lisanti MP. Oxidative stress and ketone production in cancer associated fibroblasts promote tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. *Cell Cycle* 2010, 9:3534-3531.

72. Sotgia F, Lisanti MP. Oxidative stress and ketone production in cancer associated fibroblasts promote tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. *Cell Cycle* 2010, 9:3534-3531.

73. Sotgia F, Lisanti MP. Oxidative stress and ketone production in cancer associated fibroblasts promote tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. *Cell Cycle* 2010, 9:3534-3531.
electrophoresis time-of-flight mass spectrometry. Cancer Res 2009, 69:4199-4205.

86. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Longiro RG, Liu Y, Niyati MK, Ahsan A, Kayalama-Sundaram S, Han B, Cao X, Byon J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei IT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.

87. Eisenberg-Lerner A, Kimchi A: The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis 2009, 14:376-391.

88. Macleen NH, Dorsev FC, Cleveland JL, Kastan MB: Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008, 118:79-88.

89. Sparks CA, Guettin DA: Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29:3733-3744.

90. Loges S, Mazzone M, Hohensinner P, Carmeliet P, Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS, Siddiqi NJ, Alhomida AS: Status of hepatic oxidative stress and antioxidant defense systems during chloroquine treatment of Plasmodium yoelii nigeriensis infected mice. In Vivo 1999, 13:547-550.

91. Solomon VR, Lee H: Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009, 625:220-233.

92. Murchison EP: Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene 2008, 27 Suppl 2:519-30.

93. Thomas R, Rebbeck CA, Leroy AM, Burt A, Breen M: Extensive conservation of genomic imbalances in canine transmissible venereal tumors (CTVT) detected by microarray-based CGH analysis. Chromosome Res 2009, 17:927-934.

94. McCallum H, Jones M, Hawkins C, Hamede R, Fedtton N, Lazenby B: Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-induced extinction. Ecology 2009, 90:3379-3392.

95. Kreiss A, Tovar C, Obendorf DL, Dun K, Woods GM: A murine xenograft model for a transmissible cancer in Tasmanian devils. Vet Pathol 2010, 47:485-481.

96. Copper HL, Mackay CM, Banfield WG: Chromosome studies of a contagious reticulum cell sarcoma of the Syrian hamster. J Natl Cancer Inst 1964, 33:691-706.

97. Banfield WG, Wolfe PA, Mackay CM, Cooper HL: Mosquito transmission of a reticulum cell sarcoma of hamsters. Science 1965, 148:1239-1240.

98. Gartner HV, Seidl C, Luckenbach C, Schumm G, Seifried E, Ritter H, Bultmann B: Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon. N Engl J Med 1996, 335:1494-1496.

99. Rebbeck CA, Thomas R, Breen M, Leroy AM, Burt A: Origins and evolution of a transmissible cancer. Evolution 2009, 63:2340-2349.

100. Rebbeck CA, Leroy AM, Burt A: Mitochondrial capture by a transmissible cancer. Science 2011, 331:303.

101. Villanueva T: Metabolism: the mitochondria that wag the dog. Nat Rev Cancer 2011, 11:153.

102. Stettner N, Brenner O, Elam R, Harmelin A: PEGylated liposomal doxorubicin as a chemotherapeutic agent for treatment of canine transmissible venereal tumor in murine models. J Vet Med Sci 2005, 67:1133-1139.

103. Spees JL, Olson SD, Whitney MJ, Procop DJ: Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci U S A 2006, 103:1283-1288.

104. Chen E, Hewel J, Krueger JS, Tiraby C, Weber MR, Krailli A, Becker K, Yates JR 3rd, Felding-Habermann B: Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007, 67:1472-1486.

105. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsigos A, Lin Z, Pavilides S, Wang C, Flombergen N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP: Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis, and poor clinical outcome in breast cancer: Achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011, 10:1271-1286.

106. Bonuccelli G, Tsigos A, Whitaker-Menezes D, Pavilides S, Pestell RG, Chiavarina B, Frank PG, Flombergen N, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP: Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514.

doi:10.1186/bcr2892

Cite this article as: Sotgia F et al: Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research 2011, 13:213.